Products & Services · Gross Profit

Other — Gross Profit

United Therapeutics Other — Gross Profit increased by 8.1% to -$6.80M in Q1 2026 compared to the prior quarter. Year-over-year, this metric declined by 580.0%, from -$1.00M to -$6.80M. This is a positive signal — higher values indicate stronger performance for this metric.

Analysis

StatementSegment
CategoryProfitability
SignalHigher is better
VolatilityVolatile
First reportedQ1 2020
Last reportedQ1 2026
Rolls up toGross Profit

How to read this metric

An increase signals improved profitability or better cost control in secondary segments, whereas a decrease or negative value highlights potential financial strain or high investment costs in these areas.

Detailed definition

This metric represents the profit remaining from the non-core business segments after deducting the direct costs of prod...

Peer comparison

Similar to 'Segment Gross Profit' reported by diversified companies, providing insight into the margin profile of non-core business units.

Metric ID: uthr_segment_other_gross_profit

Historical Data

19 periods
 Q2 '21Q3 '21Q4 '21Q1 '22Q2 '22Q3 '22Q1 '23Q2 '23Q3 '23Q4 '23Q1 '24Q2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26
Value$0.00$0.00$0.00$10.00M$0.00$0.00-$600.00K-$1.40M-$2.30M-$2.20M-$1.20M-$1.80M-$300.00K-$1.50M-$1.00M-$1.50M-$4.10M-$7.40M-$6.80M
QoQ Change-100.0%-133.3%-64.3%+4.3%+45.5%-50.0%+83.3%-400.0%+33.3%-50.0%-173.3%-80.5%+8.1%
YoY Change-106.0%-100.0%-28.6%+87.0%+31.8%+16.7%+16.7%<-999%-393.3%-580.0%
Range-$7.40M$10.00M
Avg YoY Growth-232.2%
Median YoY Growth-64.3%

Frequently Asked Questions

What is United Therapeutics's other — gross profit?
United Therapeutics (UTHR) reported other — gross profit of -$6.80M in Q1 2026.
How has United Therapeutics's other — gross profit changed year-over-year?
United Therapeutics's other — gross profit decreased by 580.0% year-over-year, from -$1.00M to -$6.80M.
What does other — gross profit mean?
The profit or loss generated by secondary business segments after subtracting direct production costs from revenue.